KYMR: Canaccord Genuity Raises PT
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics with a Buy and raises the price target from $106 to $129
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results.
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics with a Buy and raises the price target from $106 to $129